Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Haiti, Science, & Me.
Press releases published on August 6, 2025

Profusa, Inc. Provides Strategy Overview and Business Update for Investors
BERKELEY, Calif, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (NASDAQ: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an …

Safe Pro to Capitalize on Landmark Proposed FAA Rules Normalizing Drone Operations Utilizing Beyond Visual Line of Sight with Expanded AI-Powered Drone Services
AVENTURA, Fla., Aug. 06, 2025 (GLOBE NEWSWIRE) -- via IBN – Safe Pro Group Inc. (Nasdaq: SPAI) (“Safe Pro” or the “Company”), a leader in artificial intelligence (AI)-powered defense and security solutions today applauded efforts by the Department of …

Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC)
VGCC antibody testing in conjunction with neurologic consultation can diagnose LEMS Amifampridine may be considered as a supportive care treatment Guideline inclusion may raise clinical awareness of cancer-associated LEMS to support broader VGCC diagnostic …

Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025
CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, …

Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT
REYKJAVIK, Iceland, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results …

NKGen Biotech To Present on Allogeneic Enhanced NK Cells without Lymphodepletion in Solid Tumors at the 13th Annual Immuno-Oncology Summit
SANTA ANA, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer …

KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
ARLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today …

Sofwave to Participate in 10th Annual Needham Virtual MedTech & Diagnostics Conference
SAN CLEMENTE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today announced that Louis Scafuri, Chief …

Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting
Meeting Completion Marks Major Step Toward Phase 3 AD04 Trial Launch Strategic Partnership Discussions Expected Following the Positive FDA Meeting GLEN ALLEN, Va., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the …

PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results
PRINCETON, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced …

Cardurion Pharmaceuticals Completes Enrollment in Phase 2 CYCLE Trials Evaluating CRD-750, a Novel PDE9 inhibitor, in Heart Failure
CRD-750 is the first clinical-stage PDE9 inhibitor to be evaluated in patients in both types of chronic heart failure The CYCLE-1-REF trial is evaluating patients with heart failure with reduced ejection fraction (HFrEF), and the CYCLE-2-PEF trial is …

4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
EMERYVILLE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment …

Tessell Achieves PCI DSS 4.1, Raising the Bar for Cloud Database Security
SAN FRANCISCO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Tessell, the multi-cloud database-as-a-service (DBaaS) platform helping enterprises modernize databases and applications at scale, today announced that it has successfully achieved Payment Card Industry Data …

Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference
SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today …

AgEagle Switzerland Facility Receives ISO 9001 Certification
Achievement demonstrates manufacturer’s successful drive for excellence in drone production Wichita, Kan., Aug. 06, 2025 (GLOBE NEWSWIRE) -- AgEagle Aerial Systems Inc. (NYSE:UAVS), a leading provider of advanced drone and aerial imaging solutions, …

FOXO TECHNOLOGIES INC. ANNOUNCES EXECUTION OF A NON-BINDING ACQUISITION AGREEMENT FOR AN ASSISTED-LIVING FACILITY IN SOUTH FLORIDA FOR A TOTAL CONSIDERATION OF $22 MILLION
WEST PALM BEACH, FLORIDA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”) announces that it has executed a non-binding acquisition agreement to acquire an assisted living and memory care facility in …

EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
WATERTOWN, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced …

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran Dr. Roger Sawhney joins the Arbutus Board of Directors following resignation of Anuj Hasija Dr. Harry Janssen joins the Arbutus …

Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates
Partnership discussions for pilavapadin remain underway following Phase 2b PROGRESS study results IND-enabling studies of LX9851 for obesity and related disorders on track for completion in 2025 with licensee Novo Nordisk expected to submit IND Enrollment …

Orezone Announces Completion of Initial Public Offering on ASX
NOT FOR RELEASE TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Orezone Gold Corporation (TSX: ORE, OTCQX: ORZCF) (the “Company” or “Orezone”) is pleased to announce that it …